and Media

News Releases

Portola Pharmaceuticals to Present at the 2017 Morgan Stanley Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the 2017 Morgan Stanley Global Healthcare Conference on Wednesday, September 13, at 1:00 p.m. Eastern Time in New York City.

The presentation will be webcast live and available for replay on Portola's website at in the Investor Relations section.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit and follow the Company on Twitter @Portola_Pharma.

Investor Contact:
Michele MantynenPortola

Media Contact:
Julie NormartPure

Primary Logo

Portola Pharmaceuticals, Inc.